// App-Quantinova.ai

: Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies

Researchers

Presenter

  • Dave Singh

Principal Investigators

  • Enrico Clini

  • Alberto Papi

  • Alessio Piraino

  • Elena Nudo

  • Alessandro Guasconi

  • George Georges

  • Jorgen Vestbo

Medical Centers

  • Medicines Evaluation Unit, University of Manchester, Manchester, United Kingdom,

  • Lung Unit and Centre of Rare Lung Disease, University of Modena, Reggio Emilia, Italy

  • Research Centre on Asthma and COPD, University of Ferrara, Fe, Italy

  • Medical Affairs, Chiesi, Parma, Italy

  • Global Medical Affairs, Chiesi Farmaceutici, S.p.A., Parma, Italy

  • Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.

  • Division of Infection, Inflammation and Respiratory Medicine, University of Manchester, Manchester, United Kingdom,

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Seebri Breezhaler

  • indacaterol

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved